nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—kidney cancer—bone cancer	0.484	1	CtDrD
Pazopanib—KIT—bone cancer	0.222	0.783	CbGaD
Pazopanib—CYP3A4—bone cancer	0.0614	0.217	CbGaD
Pazopanib—ABCG2—Carboplatin—bone cancer	0.0137	0.212	CbGbCtD
Pazopanib—ABCG2—Cisplatin—bone cancer	0.0117	0.181	CbGbCtD
Pazopanib—SLCO1B1—Methotrexate—bone cancer	0.0096	0.148	CbGbCtD
Pazopanib—ABCG2—Doxorubicin—bone cancer	0.00787	0.122	CbGbCtD
Pazopanib—ABCG2—Methotrexate—bone cancer	0.00763	0.118	CbGbCtD
Pazopanib—FGFR3—epiphyseal plate—bone cancer	0.00548	0.146	CbGeAlD
Pazopanib—ABCB1—Cisplatin—bone cancer	0.00424	0.0654	CbGbCtD
Pazopanib—ABCB1—Doxorubicin—bone cancer	0.00284	0.0438	CbGbCtD
Pazopanib—Rilpivirine—NR1I2—bone cancer	0.00275	0.835	CrCbGaD
Pazopanib—ABCB1—Methotrexate—bone cancer	0.00275	0.0424	CbGbCtD
Pazopanib—CYP2D6—Doxorubicin—bone cancer	0.00267	0.0413	CbGbCtD
Pazopanib—FGFR3—skull—bone cancer	0.00229	0.061	CbGeAlD
Pazopanib—FGFR3—cartilage tissue—bone cancer	0.00195	0.0521	CbGeAlD
Pazopanib—FGF1—periosteum—bone cancer	0.00193	0.0515	CbGeAlD
Pazopanib—FGFR3—appendage—bone cancer	0.0017	0.0454	CbGeAlD
Pazopanib—CYP3A4—Doxorubicin—bone cancer	0.0017	0.0263	CbGbCtD
Pazopanib—FGFR2—skull—bone cancer	0.0015	0.04	CbGeAlD
Pazopanib—CSF1R—periosteum—bone cancer	0.0014	0.0372	CbGeAlD
Pazopanib—FGF1—cartilage tissue—bone cancer	0.00135	0.0361	CbGeAlD
Pazopanib—FGF1—appendage—bone cancer	0.00118	0.0314	CbGeAlD
Pazopanib—KDR—hindlimb—bone cancer	0.00102	0.0271	CbGeAlD
Pazopanib—KDR—appendage—bone cancer	0.000873	0.0233	CbGeAlD
Pazopanib—Rilpivirine—CYP3A4—bone cancer	0.000545	0.165	CrCbGaD
Pazopanib—LYN—connective tissue—bone cancer	0.000488	0.013	CbGeAlD
Pazopanib—FGFR3—connective tissue—bone cancer	0.000486	0.0129	CbGeAlD
Pazopanib—ITK—bone marrow—bone cancer	0.000451	0.012	CbGeAlD
Pazopanib—TAOK1—bone marrow—bone cancer	0.00041	0.0109	CbGeAlD
Pazopanib—TAOK1—spinal cord—bone cancer	0.000409	0.0109	CbGeAlD
Pazopanib—PLK4—Doxorubicin—Epirubicin—bone cancer	0.000401	0.26	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Epirubicin—bone cancer	0.000401	0.26	CbGdCrCtD
Pazopanib—SH2B3—tendon—bone cancer	0.000399	0.0106	CbGeAlD
Pazopanib—AURKC—tendon—bone cancer	0.000393	0.0105	CbGeAlD
Pazopanib—SH2B3—bone marrow—bone cancer	0.000386	0.0103	CbGeAlD
Pazopanib—SH2B3—spinal cord—bone cancer	0.000385	0.0103	CbGeAlD
Pazopanib—PLK4—Epirubicin—Doxorubicin—bone cancer	0.000371	0.24	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Doxorubicin—bone cancer	0.000371	0.24	CbGdCrCtD
Pazopanib—MAP3K2—connective tissue—bone cancer	0.000357	0.00953	CbGeAlD
Pazopanib—PLK4—bone marrow—bone cancer	0.000348	0.00927	CbGeAlD
Pazopanib—STK16—tendon—bone cancer	0.000339	0.00904	CbGeAlD
Pazopanib—FGF1—connective tissue—bone cancer	0.000337	0.00898	CbGeAlD
Pazopanib—RIOK2—tendon—bone cancer	0.000334	0.0089	CbGeAlD
Pazopanib—RIOK2—bone marrow—bone cancer	0.000323	0.00862	CbGeAlD
Pazopanib—FGFR3—spinal cord—bone cancer	0.000322	0.00858	CbGeAlD
Pazopanib—RIOK2—spinal cord—bone cancer	0.000322	0.00858	CbGeAlD
Pazopanib—FGFR2—connective tissue—bone cancer	0.000318	0.00848	CbGeAlD
Pazopanib—STK36—tendon—bone cancer	0.0003	0.008	CbGeAlD
Pazopanib—PI4KB—tendon—bone cancer	0.000295	0.00787	CbGeAlD
Pazopanib—FLT1—connective tissue—bone cancer	0.000295	0.00786	CbGeAlD
Pazopanib—PI4KB—bone marrow—bone cancer	0.000286	0.00763	CbGeAlD
Pazopanib—PI4KB—spinal cord—bone cancer	0.000285	0.00759	CbGeAlD
Pazopanib—LIMK2—spinal cord—bone cancer	0.00028	0.00745	CbGeAlD
Pazopanib—TAOK3—connective tissue—bone cancer	0.000278	0.00741	CbGeAlD
Pazopanib—PDGFRA—connective tissue—bone cancer	0.000276	0.00736	CbGeAlD
Pazopanib—PIP4K2C—tendon—bone cancer	0.000259	0.00691	CbGeAlD
Pazopanib—FGFR1—tendon—bone cancer	0.000257	0.00685	CbGeAlD
Pazopanib—FLT4—bone marrow—bone cancer	0.000252	0.00673	CbGeAlD
Pazopanib—PIP4K2C—bone marrow—bone cancer	0.000251	0.00669	CbGeAlD
Pazopanib—PIP4K2C—spinal cord—bone cancer	0.00025	0.00666	CbGeAlD
Pazopanib—KDR—connective tissue—bone cancer	0.000249	0.00664	CbGeAlD
Pazopanib—FGFR1—spinal cord—bone cancer	0.000248	0.00661	CbGeAlD
Pazopanib—CSF1R—connective tissue—bone cancer	0.000243	0.00648	CbGeAlD
Pazopanib—MAP3K2—bone marrow—bone cancer	0.000238	0.00634	CbGeAlD
Pazopanib—FGF1—spinal cord—bone cancer	0.000223	0.00595	CbGeAlD
Pazopanib—LCK—bone marrow—bone cancer	0.000223	0.00594	CbGeAlD
Pazopanib—KIT—connective tissue—bone cancer	0.000221	0.00589	CbGeAlD
Pazopanib—PDGFRB—connective tissue—bone cancer	0.000216	0.00575	CbGeAlD
Pazopanib—FGFR2—spinal cord—bone cancer	0.000211	0.00562	CbGeAlD
Pazopanib—FLT1—tendon—bone cancer	0.000203	0.0054	CbGeAlD
Pazopanib—EPHB6—tendon—bone cancer	0.0002	0.00534	CbGeAlD
Pazopanib—FLT1—spinal cord—bone cancer	0.000195	0.00521	CbGeAlD
Pazopanib—EPHB6—spinal cord—bone cancer	0.000193	0.00515	CbGeAlD
Pazopanib—STK10—tendon—bone cancer	0.000192	0.00511	CbGeAlD
Pazopanib—TAOK3—tendon—bone cancer	0.000191	0.00509	CbGeAlD
Pazopanib—PDGFRA—tendon—bone cancer	0.00019	0.00506	CbGeAlD
Pazopanib—STK10—bone marrow—bone cancer	0.000186	0.00495	CbGeAlD
Pazopanib—TAOK3—bone marrow—bone cancer	0.000185	0.00493	CbGeAlD
Pazopanib—TAOK3—spinal cord—bone cancer	0.000184	0.00491	CbGeAlD
Pazopanib—PDGFRA—spinal cord—bone cancer	0.000183	0.00488	CbGeAlD
Pazopanib—KDR—tendon—bone cancer	0.000171	0.00457	CbGeAlD
Pazopanib—MAP2K5—tendon—bone cancer	0.000171	0.00457	CbGeAlD
Pazopanib—CSF1R—tendon—bone cancer	0.000167	0.00446	CbGeAlD
Pazopanib—KDR—bone marrow—bone cancer	0.000166	0.00442	CbGeAlD
Pazopanib—KDR—spinal cord—bone cancer	0.000165	0.0044	CbGeAlD
Pazopanib—MAP2K5—spinal cord—bone cancer	0.000165	0.0044	CbGeAlD
Pazopanib—CSF1R—bone marrow—bone cancer	0.000162	0.00432	CbGeAlD
Pazopanib—CSF1R—spinal cord—bone cancer	0.000161	0.0043	CbGeAlD
Pazopanib—PDGFRB—tendon—bone cancer	0.000148	0.00395	CbGeAlD
Pazopanib—KIT—bone marrow—bone cancer	0.000147	0.00392	CbGeAlD
Pazopanib—KIT—spinal cord—bone cancer	0.000146	0.0039	CbGeAlD
Pazopanib—PDGFRB—bone marrow—bone cancer	0.000144	0.00383	CbGeAlD
Pazopanib—PDGFRB—spinal cord—bone cancer	0.000143	0.00381	CbGeAlD
Pazopanib—Face oedema—Epirubicin—bone cancer	9.78e-05	0.00179	CcSEcCtD
Pazopanib—Oedema—Cisplatin—bone cancer	9.69e-05	0.00178	CcSEcCtD
Pazopanib—Infection—Cisplatin—bone cancer	9.63e-05	0.00177	CcSEcCtD
Pazopanib—Cardiac failure—Doxorubicin—bone cancer	9.6e-05	0.00176	CcSEcCtD
Pazopanib—Lethargy—Doxorubicin—bone cancer	9.56e-05	0.00175	CcSEcCtD
Pazopanib—Cerebrovascular accident—Doxorubicin—bone cancer	9.56e-05	0.00175	CcSEcCtD
Pazopanib—Nervous system disorder—Cisplatin—bone cancer	9.51e-05	0.00174	CcSEcCtD
Pazopanib—Thrombocytopenia—Cisplatin—bone cancer	9.49e-05	0.00174	CcSEcCtD
Pazopanib—Blood creatinine increased—Epirubicin—bone cancer	9.49e-05	0.00174	CcSEcCtD
Pazopanib—Dehydration—Epirubicin—bone cancer	9.42e-05	0.00173	CcSEcCtD
Pazopanib—Skin disorder—Cisplatin—bone cancer	9.42e-05	0.00173	CcSEcCtD
Pazopanib—Hyponatraemia—Doxorubicin—bone cancer	9.41e-05	0.00173	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	9.37e-05	0.00172	CcSEcCtD
Pazopanib—Hyperhidrosis—Cisplatin—bone cancer	9.37e-05	0.00172	CcSEcCtD
Pazopanib—Liver function test abnormal—Epirubicin—bone cancer	9.35e-05	0.00172	CcSEcCtD
Pazopanib—Dry skin—Epirubicin—bone cancer	9.28e-05	0.0017	CcSEcCtD
Pazopanib—Abdominal pain upper—Epirubicin—bone cancer	9.25e-05	0.0017	CcSEcCtD
Pazopanib—Anorexia—Cisplatin—bone cancer	9.24e-05	0.0017	CcSEcCtD
Pazopanib—Pancreatitis—Methotrexate—bone cancer	9.17e-05	0.00168	CcSEcCtD
Pazopanib—Breast disorder—Epirubicin—bone cancer	9.15e-05	0.00168	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Epirubicin—bone cancer	9.12e-05	0.00167	CcSEcCtD
Pazopanib—Nasopharyngitis—Epirubicin—bone cancer	9.06e-05	0.00166	CcSEcCtD
Pazopanib—Face oedema—Doxorubicin—bone cancer	9.05e-05	0.00166	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Epirubicin—bone cancer	8.93e-05	0.00164	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Cisplatin—bone cancer	8.83e-05	0.00162	CcSEcCtD
Pazopanib—Abdominal distension—Epirubicin—bone cancer	8.81e-05	0.00162	CcSEcCtD
Pazopanib—Blood creatinine increased—Doxorubicin—bone cancer	8.78e-05	0.00161	CcSEcCtD
Pazopanib—Neutropenia—Methotrexate—bone cancer	8.75e-05	0.0016	CcSEcCtD
Pazopanib—Dehydration—Doxorubicin—bone cancer	8.71e-05	0.0016	CcSEcCtD
Pazopanib—Paraesthesia—Cisplatin—bone cancer	8.7e-05	0.0016	CcSEcCtD
Pazopanib—Liver function test abnormal—Doxorubicin—bone cancer	8.65e-05	0.00159	CcSEcCtD
Pazopanib—Dyspnoea—Cisplatin—bone cancer	8.64e-05	0.00159	CcSEcCtD
Pazopanib—Dry skin—Doxorubicin—bone cancer	8.59e-05	0.00158	CcSEcCtD
Pazopanib—Pancreatitis—Epirubicin—bone cancer	8.58e-05	0.00157	CcSEcCtD
Pazopanib—Abdominal pain upper—Doxorubicin—bone cancer	8.56e-05	0.00157	CcSEcCtD
Pazopanib—Photosensitivity reaction—Methotrexate—bone cancer	8.54e-05	0.00157	CcSEcCtD
Pazopanib—Breast disorder—Doxorubicin—bone cancer	8.47e-05	0.00155	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Doxorubicin—bone cancer	8.44e-05	0.00155	CcSEcCtD
Pazopanib—Decreased appetite—Cisplatin—bone cancer	8.43e-05	0.00155	CcSEcCtD
Pazopanib—Nasopharyngitis—Doxorubicin—bone cancer	8.38e-05	0.00154	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Cisplatin—bone cancer	8.37e-05	0.00154	CcSEcCtD
Pazopanib—Infestation NOS—Methotrexate—bone cancer	8.34e-05	0.00153	CcSEcCtD
Pazopanib—Infestation—Methotrexate—bone cancer	8.34e-05	0.00153	CcSEcCtD
Pazopanib—Pain—Cisplatin—bone cancer	8.29e-05	0.00152	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Doxorubicin—bone cancer	8.27e-05	0.00152	CcSEcCtD
Pazopanib—Neutropenia—Epirubicin—bone cancer	8.19e-05	0.0015	CcSEcCtD
Pazopanib—Abdominal distension—Doxorubicin—bone cancer	8.15e-05	0.0015	CcSEcCtD
Pazopanib—Stomatitis—Methotrexate—bone cancer	8.13e-05	0.00149	CcSEcCtD
Pazopanib—ABCG2—bone marrow—bone cancer	8.07e-05	0.00215	CbGeAlD
Pazopanib—ABCG2—spinal cord—bone cancer	8.04e-05	0.00214	CbGeAlD
Pazopanib—Photosensitivity reaction—Epirubicin—bone cancer	7.99e-05	0.00147	CcSEcCtD
Pazopanib—Haematuria—Methotrexate—bone cancer	7.95e-05	0.00146	CcSEcCtD
Pazopanib—Pancreatitis—Doxorubicin—bone cancer	7.94e-05	0.00146	CcSEcCtD
Pazopanib—Weight decreased—Epirubicin—bone cancer	7.92e-05	0.00145	CcSEcCtD
Pazopanib—Hepatobiliary disease—Methotrexate—bone cancer	7.89e-05	0.00145	CcSEcCtD
Pazopanib—Epistaxis—Methotrexate—bone cancer	7.87e-05	0.00144	CcSEcCtD
Pazopanib—Infestation NOS—Epirubicin—bone cancer	7.8e-05	0.00143	CcSEcCtD
Pazopanib—Infestation—Epirubicin—bone cancer	7.8e-05	0.00143	CcSEcCtD
Pazopanib—Jaundice—Epirubicin—bone cancer	7.61e-05	0.0014	CcSEcCtD
Pazopanib—Stomatitis—Epirubicin—bone cancer	7.61e-05	0.0014	CcSEcCtD
Pazopanib—Neutropenia—Doxorubicin—bone cancer	7.57e-05	0.00139	CcSEcCtD
Pazopanib—Haemoglobin—Methotrexate—bone cancer	7.52e-05	0.00138	CcSEcCtD
Pazopanib—Haemorrhage—Methotrexate—bone cancer	7.49e-05	0.00137	CcSEcCtD
Pazopanib—Haematuria—Epirubicin—bone cancer	7.44e-05	0.00137	CcSEcCtD
Pazopanib—Urinary tract disorder—Methotrexate—bone cancer	7.39e-05	0.00136	CcSEcCtD
Pazopanib—Photosensitivity reaction—Doxorubicin—bone cancer	7.39e-05	0.00136	CcSEcCtD
Pazopanib—Hepatobiliary disease—Epirubicin—bone cancer	7.38e-05	0.00135	CcSEcCtD
Pazopanib—Epistaxis—Epirubicin—bone cancer	7.36e-05	0.00135	CcSEcCtD
Pazopanib—Urethral disorder—Methotrexate—bone cancer	7.34e-05	0.00135	CcSEcCtD
Pazopanib—Weight decreased—Doxorubicin—bone cancer	7.33e-05	0.00134	CcSEcCtD
Pazopanib—Infestation NOS—Doxorubicin—bone cancer	7.22e-05	0.00133	CcSEcCtD
Pazopanib—Infestation—Doxorubicin—bone cancer	7.22e-05	0.00133	CcSEcCtD
Pazopanib—Bradycardia—Epirubicin—bone cancer	7.13e-05	0.00131	CcSEcCtD
Pazopanib—Haemoglobin—Epirubicin—bone cancer	7.04e-05	0.00129	CcSEcCtD
Pazopanib—Stomatitis—Doxorubicin—bone cancer	7.04e-05	0.00129	CcSEcCtD
Pazopanib—Jaundice—Doxorubicin—bone cancer	7.04e-05	0.00129	CcSEcCtD
Pazopanib—Haemorrhage—Epirubicin—bone cancer	7.01e-05	0.00129	CcSEcCtD
Pazopanib—Eye disorder—Methotrexate—bone cancer	7e-05	0.00128	CcSEcCtD
Pazopanib—Hypoaesthesia—Epirubicin—bone cancer	6.97e-05	0.00128	CcSEcCtD
Pazopanib—Asthenia—Cisplatin—bone cancer	6.95e-05	0.00128	CcSEcCtD
Pazopanib—Cardiac disorder—Methotrexate—bone cancer	6.95e-05	0.00127	CcSEcCtD
Pazopanib—Urinary tract disorder—Epirubicin—bone cancer	6.92e-05	0.00127	CcSEcCtD
Pazopanib—Oedema peripheral—Epirubicin—bone cancer	6.9e-05	0.00127	CcSEcCtD
Pazopanib—Haematuria—Doxorubicin—bone cancer	6.89e-05	0.00126	CcSEcCtD
Pazopanib—Connective tissue disorder—Epirubicin—bone cancer	6.89e-05	0.00126	CcSEcCtD
Pazopanib—Urethral disorder—Epirubicin—bone cancer	6.87e-05	0.00126	CcSEcCtD
Pazopanib—Hepatobiliary disease—Doxorubicin—bone cancer	6.83e-05	0.00125	CcSEcCtD
Pazopanib—Epistaxis—Doxorubicin—bone cancer	6.81e-05	0.00125	CcSEcCtD
Pazopanib—Angiopathy—Methotrexate—bone cancer	6.79e-05	0.00125	CcSEcCtD
Pazopanib—Mediastinal disorder—Methotrexate—bone cancer	6.75e-05	0.00124	CcSEcCtD
Pazopanib—Chills—Methotrexate—bone cancer	6.72e-05	0.00123	CcSEcCtD
Pazopanib—Diarrhoea—Cisplatin—bone cancer	6.63e-05	0.00122	CcSEcCtD
Pazopanib—Alopecia—Methotrexate—bone cancer	6.62e-05	0.00121	CcSEcCtD
Pazopanib—Bradycardia—Doxorubicin—bone cancer	6.6e-05	0.00121	CcSEcCtD
Pazopanib—Mental disorder—Methotrexate—bone cancer	6.56e-05	0.0012	CcSEcCtD
Pazopanib—Eye disorder—Epirubicin—bone cancer	6.55e-05	0.0012	CcSEcCtD
Pazopanib—Malnutrition—Methotrexate—bone cancer	6.52e-05	0.0012	CcSEcCtD
Pazopanib—Erythema—Methotrexate—bone cancer	6.52e-05	0.0012	CcSEcCtD
Pazopanib—Haemoglobin—Doxorubicin—bone cancer	6.52e-05	0.0012	CcSEcCtD
Pazopanib—Cardiac disorder—Epirubicin—bone cancer	6.5e-05	0.00119	CcSEcCtD
Pazopanib—Flushing—Epirubicin—bone cancer	6.5e-05	0.00119	CcSEcCtD
Pazopanib—Haemorrhage—Doxorubicin—bone cancer	6.48e-05	0.00119	CcSEcCtD
Pazopanib—Hypoaesthesia—Doxorubicin—bone cancer	6.45e-05	0.00118	CcSEcCtD
Pazopanib—Urinary tract disorder—Doxorubicin—bone cancer	6.4e-05	0.00117	CcSEcCtD
Pazopanib—Oedema peripheral—Doxorubicin—bone cancer	6.39e-05	0.00117	CcSEcCtD
Pazopanib—Dysgeusia—Methotrexate—bone cancer	6.38e-05	0.00117	CcSEcCtD
Pazopanib—Connective tissue disorder—Doxorubicin—bone cancer	6.37e-05	0.00117	CcSEcCtD
Pazopanib—Angiopathy—Epirubicin—bone cancer	6.36e-05	0.00117	CcSEcCtD
Pazopanib—Urethral disorder—Doxorubicin—bone cancer	6.35e-05	0.00117	CcSEcCtD
Pazopanib—Mediastinal disorder—Epirubicin—bone cancer	6.31e-05	0.00116	CcSEcCtD
Pazopanib—Chills—Epirubicin—bone cancer	6.29e-05	0.00115	CcSEcCtD
Pazopanib—Alopecia—Epirubicin—bone cancer	6.19e-05	0.00114	CcSEcCtD
Pazopanib—Vomiting—Cisplatin—bone cancer	6.16e-05	0.00113	CcSEcCtD
Pazopanib—Vision blurred—Methotrexate—bone cancer	6.14e-05	0.00113	CcSEcCtD
Pazopanib—Mental disorder—Epirubicin—bone cancer	6.14e-05	0.00113	CcSEcCtD
Pazopanib—Rash—Cisplatin—bone cancer	6.11e-05	0.00112	CcSEcCtD
Pazopanib—Dermatitis—Cisplatin—bone cancer	6.11e-05	0.00112	CcSEcCtD
Pazopanib—Malnutrition—Epirubicin—bone cancer	6.1e-05	0.00112	CcSEcCtD
Pazopanib—Erythema—Epirubicin—bone cancer	6.1e-05	0.00112	CcSEcCtD
Pazopanib—Eye disorder—Doxorubicin—bone cancer	6.06e-05	0.00111	CcSEcCtD
Pazopanib—Anaemia—Methotrexate—bone cancer	6.02e-05	0.00111	CcSEcCtD
Pazopanib—Cardiac disorder—Doxorubicin—bone cancer	6.02e-05	0.0011	CcSEcCtD
Pazopanib—Flushing—Doxorubicin—bone cancer	6.02e-05	0.0011	CcSEcCtD
Pazopanib—Flatulence—Epirubicin—bone cancer	6.01e-05	0.0011	CcSEcCtD
Pazopanib—Dysgeusia—Epirubicin—bone cancer	5.97e-05	0.0011	CcSEcCtD
Pazopanib—Angiopathy—Doxorubicin—bone cancer	5.88e-05	0.00108	CcSEcCtD
Pazopanib—Muscle spasms—Epirubicin—bone cancer	5.86e-05	0.00108	CcSEcCtD
Pazopanib—Mediastinal disorder—Doxorubicin—bone cancer	5.84e-05	0.00107	CcSEcCtD
Pazopanib—Leukopenia—Methotrexate—bone cancer	5.83e-05	0.00107	CcSEcCtD
Pazopanib—Chills—Doxorubicin—bone cancer	5.82e-05	0.00107	CcSEcCtD
Pazopanib—Nausea—Cisplatin—bone cancer	5.76e-05	0.00106	CcSEcCtD
Pazopanib—Vision blurred—Epirubicin—bone cancer	5.75e-05	0.00105	CcSEcCtD
Pazopanib—Alopecia—Doxorubicin—bone cancer	5.73e-05	0.00105	CcSEcCtD
Pazopanib—Cough—Methotrexate—bone cancer	5.69e-05	0.00104	CcSEcCtD
Pazopanib—Mental disorder—Doxorubicin—bone cancer	5.68e-05	0.00104	CcSEcCtD
Pazopanib—Erythema—Doxorubicin—bone cancer	5.64e-05	0.00104	CcSEcCtD
Pazopanib—Malnutrition—Doxorubicin—bone cancer	5.64e-05	0.00104	CcSEcCtD
Pazopanib—Anaemia—Epirubicin—bone cancer	5.64e-05	0.00103	CcSEcCtD
Pazopanib—Flatulence—Doxorubicin—bone cancer	5.56e-05	0.00102	CcSEcCtD
Pazopanib—Chest pain—Methotrexate—bone cancer	5.55e-05	0.00102	CcSEcCtD
Pazopanib—Arthralgia—Methotrexate—bone cancer	5.55e-05	0.00102	CcSEcCtD
Pazopanib—Myalgia—Methotrexate—bone cancer	5.55e-05	0.00102	CcSEcCtD
Pazopanib—Dysgeusia—Doxorubicin—bone cancer	5.53e-05	0.00101	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	5.51e-05	0.00101	CcSEcCtD
Pazopanib—Syncope—Epirubicin—bone cancer	5.47e-05	0.001	CcSEcCtD
Pazopanib—Leukopenia—Epirubicin—bone cancer	5.46e-05	0.001	CcSEcCtD
Pazopanib—Muscle spasms—Doxorubicin—bone cancer	5.43e-05	0.000996	CcSEcCtD
Pazopanib—Loss of consciousness—Epirubicin—bone cancer	5.36e-05	0.000984	CcSEcCtD
Pazopanib—Cough—Epirubicin—bone cancer	5.32e-05	0.000977	CcSEcCtD
Pazopanib—Vision blurred—Doxorubicin—bone cancer	5.32e-05	0.000976	CcSEcCtD
Pazopanib—Infection—Methotrexate—bone cancer	5.28e-05	0.00097	CcSEcCtD
Pazopanib—Hypertension—Epirubicin—bone cancer	5.27e-05	0.000966	CcSEcCtD
Pazopanib—Nervous system disorder—Methotrexate—bone cancer	5.22e-05	0.000957	CcSEcCtD
Pazopanib—Anaemia—Doxorubicin—bone cancer	5.22e-05	0.000957	CcSEcCtD
Pazopanib—Thrombocytopenia—Methotrexate—bone cancer	5.21e-05	0.000956	CcSEcCtD
Pazopanib—Arthralgia—Epirubicin—bone cancer	5.19e-05	0.000953	CcSEcCtD
Pazopanib—Myalgia—Epirubicin—bone cancer	5.19e-05	0.000953	CcSEcCtD
Pazopanib—Chest pain—Epirubicin—bone cancer	5.19e-05	0.000953	CcSEcCtD
Pazopanib—Skin disorder—Methotrexate—bone cancer	5.17e-05	0.000948	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	5.16e-05	0.000946	CcSEcCtD
Pazopanib—Hyperhidrosis—Methotrexate—bone cancer	5.14e-05	0.000944	CcSEcCtD
Pazopanib—Dry mouth—Epirubicin—bone cancer	5.08e-05	0.000932	CcSEcCtD
Pazopanib—Anorexia—Methotrexate—bone cancer	5.07e-05	0.00093	CcSEcCtD
Pazopanib—Syncope—Doxorubicin—bone cancer	5.06e-05	0.000929	CcSEcCtD
Pazopanib—Leukopenia—Doxorubicin—bone cancer	5.05e-05	0.000927	CcSEcCtD
Pazopanib—Oedema—Epirubicin—bone cancer	4.98e-05	0.000913	CcSEcCtD
Pazopanib—Loss of consciousness—Doxorubicin—bone cancer	4.96e-05	0.00091	CcSEcCtD
Pazopanib—Infection—Epirubicin—bone cancer	4.95e-05	0.000907	CcSEcCtD
Pazopanib—Cough—Doxorubicin—bone cancer	4.92e-05	0.000904	CcSEcCtD
Pazopanib—Shock—Epirubicin—bone cancer	4.9e-05	0.000899	CcSEcCtD
Pazopanib—Nervous system disorder—Epirubicin—bone cancer	4.88e-05	0.000896	CcSEcCtD
Pazopanib—Thrombocytopenia—Epirubicin—bone cancer	4.87e-05	0.000894	CcSEcCtD
Pazopanib—Hypertension—Doxorubicin—bone cancer	4.87e-05	0.000894	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methotrexate—bone cancer	4.85e-05	0.000889	CcSEcCtD
Pazopanib—Skin disorder—Epirubicin—bone cancer	4.84e-05	0.000887	CcSEcCtD
Pazopanib—Hyperhidrosis—Epirubicin—bone cancer	4.81e-05	0.000883	CcSEcCtD
Pazopanib—Insomnia—Methotrexate—bone cancer	4.81e-05	0.000883	CcSEcCtD
Pazopanib—Myalgia—Doxorubicin—bone cancer	4.8e-05	0.000882	CcSEcCtD
Pazopanib—Arthralgia—Doxorubicin—bone cancer	4.8e-05	0.000882	CcSEcCtD
Pazopanib—Chest pain—Doxorubicin—bone cancer	4.8e-05	0.000882	CcSEcCtD
Pazopanib—Paraesthesia—Methotrexate—bone cancer	4.78e-05	0.000876	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	4.77e-05	0.000876	CcSEcCtD
Pazopanib—Anorexia—Epirubicin—bone cancer	4.74e-05	0.000871	CcSEcCtD
Pazopanib—Dyspnoea—Methotrexate—bone cancer	4.74e-05	0.00087	CcSEcCtD
Pazopanib—Somnolence—Methotrexate—bone cancer	4.73e-05	0.000868	CcSEcCtD
Pazopanib—Dry mouth—Doxorubicin—bone cancer	4.7e-05	0.000862	CcSEcCtD
Pazopanib—Dyspepsia—Methotrexate—bone cancer	4.68e-05	0.000859	CcSEcCtD
Pazopanib—Decreased appetite—Methotrexate—bone cancer	4.62e-05	0.000848	CcSEcCtD
Pazopanib—Oedema—Doxorubicin—bone cancer	4.61e-05	0.000845	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Methotrexate—bone cancer	4.59e-05	0.000843	CcSEcCtD
Pazopanib—Fatigue—Methotrexate—bone cancer	4.59e-05	0.000841	CcSEcCtD
Pazopanib—Infection—Doxorubicin—bone cancer	4.58e-05	0.00084	CcSEcCtD
Pazopanib—Pain—Methotrexate—bone cancer	4.55e-05	0.000835	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Epirubicin—bone cancer	4.54e-05	0.000832	CcSEcCtD
Pazopanib—Shock—Doxorubicin—bone cancer	4.53e-05	0.000831	CcSEcCtD
Pazopanib—Nervous system disorder—Doxorubicin—bone cancer	4.52e-05	0.000829	CcSEcCtD
Pazopanib—Thrombocytopenia—Doxorubicin—bone cancer	4.51e-05	0.000827	CcSEcCtD
Pazopanib—Insomnia—Epirubicin—bone cancer	4.5e-05	0.000826	CcSEcCtD
Pazopanib—Skin disorder—Doxorubicin—bone cancer	4.47e-05	0.000821	CcSEcCtD
Pazopanib—Paraesthesia—Epirubicin—bone cancer	4.47e-05	0.00082	CcSEcCtD
Pazopanib—Hyperhidrosis—Doxorubicin—bone cancer	4.45e-05	0.000817	CcSEcCtD
Pazopanib—Dyspnoea—Epirubicin—bone cancer	4.44e-05	0.000814	CcSEcCtD
Pazopanib—Somnolence—Epirubicin—bone cancer	4.43e-05	0.000812	CcSEcCtD
Pazopanib—Anorexia—Doxorubicin—bone cancer	4.39e-05	0.000806	CcSEcCtD
Pazopanib—Dyspepsia—Epirubicin—bone cancer	4.38e-05	0.000804	CcSEcCtD
Pazopanib—Gastrointestinal pain—Methotrexate—bone cancer	4.35e-05	0.000798	CcSEcCtD
Pazopanib—Decreased appetite—Epirubicin—bone cancer	4.33e-05	0.000794	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Epirubicin—bone cancer	4.3e-05	0.000789	CcSEcCtD
Pazopanib—Fatigue—Epirubicin—bone cancer	4.29e-05	0.000787	CcSEcCtD
Pazopanib—Pain—Epirubicin—bone cancer	4.26e-05	0.000781	CcSEcCtD
Pazopanib—Abdominal pain—Methotrexate—bone cancer	4.2e-05	0.000772	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Doxorubicin—bone cancer	4.2e-05	0.00077	CcSEcCtD
Pazopanib—Insomnia—Doxorubicin—bone cancer	4.17e-05	0.000764	CcSEcCtD
Pazopanib—Paraesthesia—Doxorubicin—bone cancer	4.14e-05	0.000759	CcSEcCtD
Pazopanib—Dyspnoea—Doxorubicin—bone cancer	4.11e-05	0.000753	CcSEcCtD
Pazopanib—Somnolence—Doxorubicin—bone cancer	4.09e-05	0.000751	CcSEcCtD
Pazopanib—Gastrointestinal pain—Epirubicin—bone cancer	4.07e-05	0.000747	CcSEcCtD
Pazopanib—Dyspepsia—Doxorubicin—bone cancer	4.05e-05	0.000744	CcSEcCtD
Pazopanib—Decreased appetite—Doxorubicin—bone cancer	4e-05	0.000735	CcSEcCtD
Pazopanib—ABCB1—bone marrow—bone cancer	3.98e-05	0.00106	CbGeAlD
Pazopanib—Gastrointestinal disorder—Doxorubicin—bone cancer	3.98e-05	0.00073	CcSEcCtD
Pazopanib—Fatigue—Doxorubicin—bone cancer	3.97e-05	0.000729	CcSEcCtD
Pazopanib—ABCB1—spinal cord—bone cancer	3.96e-05	0.00106	CbGeAlD
Pazopanib—Pain—Doxorubicin—bone cancer	3.94e-05	0.000723	CcSEcCtD
Pazopanib—Abdominal pain—Epirubicin—bone cancer	3.94e-05	0.000722	CcSEcCtD
Pazopanib—Asthenia—Methotrexate—bone cancer	3.82e-05	0.0007	CcSEcCtD
Pazopanib—Gastrointestinal pain—Doxorubicin—bone cancer	3.77e-05	0.000691	CcSEcCtD
Pazopanib—Pruritus—Methotrexate—bone cancer	3.76e-05	0.000691	CcSEcCtD
Pazopanib—Abdominal pain—Doxorubicin—bone cancer	3.64e-05	0.000668	CcSEcCtD
Pazopanib—Diarrhoea—Methotrexate—bone cancer	3.64e-05	0.000668	CcSEcCtD
Pazopanib—Asthenia—Epirubicin—bone cancer	3.57e-05	0.000655	CcSEcCtD
Pazopanib—Pruritus—Epirubicin—bone cancer	3.52e-05	0.000646	CcSEcCtD
Pazopanib—Dizziness—Methotrexate—bone cancer	3.52e-05	0.000645	CcSEcCtD
Pazopanib—Diarrhoea—Epirubicin—bone cancer	3.41e-05	0.000625	CcSEcCtD
Pazopanib—Vomiting—Methotrexate—bone cancer	3.38e-05	0.000621	CcSEcCtD
Pazopanib—Rash—Methotrexate—bone cancer	3.35e-05	0.000615	CcSEcCtD
Pazopanib—Dermatitis—Methotrexate—bone cancer	3.35e-05	0.000615	CcSEcCtD
Pazopanib—Headache—Methotrexate—bone cancer	3.33e-05	0.000611	CcSEcCtD
Pazopanib—Asthenia—Doxorubicin—bone cancer	3.3e-05	0.000606	CcSEcCtD
Pazopanib—Dizziness—Epirubicin—bone cancer	3.29e-05	0.000604	CcSEcCtD
Pazopanib—Pruritus—Doxorubicin—bone cancer	3.26e-05	0.000598	CcSEcCtD
Pazopanib—Vomiting—Epirubicin—bone cancer	3.16e-05	0.000581	CcSEcCtD
Pazopanib—Nausea—Methotrexate—bone cancer	3.16e-05	0.00058	CcSEcCtD
Pazopanib—Diarrhoea—Doxorubicin—bone cancer	3.15e-05	0.000578	CcSEcCtD
Pazopanib—Rash—Epirubicin—bone cancer	3.14e-05	0.000576	CcSEcCtD
Pazopanib—Dermatitis—Epirubicin—bone cancer	3.14e-05	0.000575	CcSEcCtD
Pazopanib—Headache—Epirubicin—bone cancer	3.12e-05	0.000572	CcSEcCtD
Pazopanib—Dizziness—Doxorubicin—bone cancer	3.05e-05	0.000559	CcSEcCtD
Pazopanib—Nausea—Epirubicin—bone cancer	2.96e-05	0.000543	CcSEcCtD
Pazopanib—Vomiting—Doxorubicin—bone cancer	2.93e-05	0.000537	CcSEcCtD
Pazopanib—Rash—Doxorubicin—bone cancer	2.9e-05	0.000533	CcSEcCtD
Pazopanib—Dermatitis—Doxorubicin—bone cancer	2.9e-05	0.000532	CcSEcCtD
Pazopanib—Headache—Doxorubicin—bone cancer	2.89e-05	0.000529	CcSEcCtD
Pazopanib—Nausea—Doxorubicin—bone cancer	2.74e-05	0.000502	CcSEcCtD
Pazopanib—FGFR1—Signaling Pathways—IL3—bone cancer	6.2e-06	8.7e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL3—bone cancer	6.18e-06	8.67e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—GNA11—bone cancer	6.17e-06	8.65e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—GNA11—bone cancer	6.14e-06	8.62e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—PTGS2—bone cancer	6.12e-06	8.58e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—DHFR—bone cancer	6.11e-06	8.57e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—CYP3A4—bone cancer	6.1e-06	8.56e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NDUFA12—bone cancer	6.04e-06	8.48e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—GNA11—bone cancer	6.01e-06	8.44e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	6.01e-06	8.44e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—KIT—bone cancer	6e-06	8.42e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—JUN—bone cancer	5.97e-06	8.38e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—JUN—bone cancer	5.91e-06	8.29e-05	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—EGFR—bone cancer	5.85e-06	8.21e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—EGFR—bone cancer	5.83e-06	8.17e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—MDM2—bone cancer	5.82e-06	8.16e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—JUN—bone cancer	5.78e-06	8.12e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—MDM2—bone cancer	5.71e-06	8.01e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—GNA11—bone cancer	5.71e-06	8.01e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ATF1—bone cancer	5.71e-06	8.01e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TGFBR2—bone cancer	5.69e-06	7.98e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—KIT—bone cancer	5.64e-06	7.92e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—KIT—bone cancer	5.59e-06	7.85e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—CYP3A4—bone cancer	5.59e-06	7.85e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ATF1—bone cancer	5.59e-06	7.84e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TGFBR2—bone cancer	5.58e-06	7.84e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—KIT—bone cancer	5.58e-06	7.83e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL3—bone cancer	5.57e-06	7.81e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.56e-06	7.81e-05	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—EGFR—bone cancer	5.55e-06	7.78e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—KIT—bone cancer	5.54e-06	7.77e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—TGFBR2—bone cancer	5.46e-06	7.66e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—MDM2—bone cancer	5.45e-06	7.65e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL3—bone cancer	5.45e-06	7.65e-05	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—EGFR—bone cancer	5.45e-06	7.64e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SMO—bone cancer	5.39e-06	7.56e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IGF1R—bone cancer	5.35e-06	7.51e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—EGFR—bone cancer	5.33e-06	7.48e-05	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—EGFR—bone cancer	5.33e-06	7.47e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—BRAF—bone cancer	5.3e-06	7.44e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TGFBR2—bone cancer	5.3e-06	7.44e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TGFBR2—bone cancer	5.29e-06	7.42e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—MDM2—bone cancer	5.27e-06	7.4e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IGF1R—bone cancer	5.25e-06	7.37e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—MDM2—bone cancer	5.24e-06	7.35e-05	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—EGFR—bone cancer	5.23e-06	7.34e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—GSTP1—bone cancer	5.22e-06	7.32e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—BRAF—bone cancer	5.21e-06	7.31e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—CYP3A4—bone cancer	5.18e-06	7.26e-05	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—EGFR—bone cancer	5.17e-06	7.25e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—KIT—bone cancer	5.16e-06	7.25e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—EGFR—bone cancer	5.16e-06	7.23e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—KIT—bone cancer	5.15e-06	7.23e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—EGFR—bone cancer	5.15e-06	7.22e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—BRAF—bone cancer	5.12e-06	7.18e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—PTGS2—bone cancer	5.08e-06	7.13e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—JUN—bone cancer	5.06e-06	7.09e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—KIT—bone cancer	5.04e-06	7.08e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—KIT—bone cancer	5.03e-06	7.05e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NT5C3A—bone cancer	5.01e-06	7.03e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IGF1R—bone cancer	4.99e-06	7e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IGF1R—bone cancer	4.97e-06	6.98e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—JUN—bone cancer	4.96e-06	6.97e-05	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—EGFR—bone cancer	4.96e-06	6.96e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—EGFR—bone cancer	4.95e-06	6.95e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—GNA11—bone cancer	4.93e-06	6.92e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—KIT—bone cancer	4.92e-06	6.91e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—MMP9—bone cancer	4.92e-06	6.9e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—KIT—bone cancer	4.91e-06	6.9e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—TP53—bone cancer	4.89e-06	6.86e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—BRAF—bone cancer	4.85e-06	6.81e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—BRAF—bone cancer	4.84e-06	6.79e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—GSTP1—bone cancer	4.78e-06	6.71e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TGFBR2—bone cancer	4.76e-06	6.68e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—JUN—bone cancer	4.74e-06	6.65e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—BRAF—bone cancer	4.74e-06	6.65e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.73e-06	6.63e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—MDM2—bone cancer	4.73e-06	6.63e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—EGFR—bone cancer	4.7e-06	6.59e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—KIT—bone cancer	4.69e-06	6.58e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TGFBR2—bone cancer	4.66e-06	6.54e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—EGFR—bone cancer	4.64e-06	6.52e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—MDM2—bone cancer	4.64e-06	6.51e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—KIT—bone cancer	4.64e-06	6.51e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—BRAF—bone cancer	4.62e-06	6.48e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ATF1—bone cancer	4.58e-06	6.43e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—EGFR—bone cancer	4.55e-06	6.38e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IGF1R—bone cancer	4.48e-06	6.29e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—TP53—bone cancer	4.47e-06	6.28e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL3—bone cancer	4.47e-06	6.27e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—EGFR—bone cancer	4.46e-06	6.26e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MDM2—bone cancer	4.44e-06	6.23e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—GSTP1—bone cancer	4.43e-06	6.21e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—BRAF—bone cancer	4.41e-06	6.18e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—MDM2—bone cancer	4.41e-06	6.18e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—MDM2—bone cancer	4.39e-06	6.17e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IGF1R—bone cancer	4.39e-06	6.16e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—EGFR—bone cancer	4.37e-06	6.13e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—MDM2—bone cancer	4.36e-06	6.12e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—BRAF—bone cancer	4.36e-06	6.12e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—EGFR—bone cancer	4.34e-06	6.08e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—MDM2—bone cancer	4.29e-06	6.01e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—TP53—bone cancer	4.24e-06	5.95e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—PTGS2—bone cancer	4.21e-06	5.9e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—PTGS2—bone cancer	4.13e-06	5.8e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—JUN—bone cancer	4.11e-06	5.76e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ENO2—bone cancer	4.09e-06	5.74e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—MDM2—bone cancer	4.07e-06	5.71e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—MDM2—bone cancer	4.06e-06	5.69e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—JUN—bone cancer	4.03e-06	5.66e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—KIT—bone cancer	4.03e-06	5.66e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—EGFR—bone cancer	3.98e-06	5.58e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MDM2—bone cancer	3.97e-06	5.57e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.97e-06	5.57e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—MDM2—bone cancer	3.96e-06	5.55e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—PTGS2—bone cancer	3.92e-06	5.5e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—PTGS2—bone cancer	3.91e-06	5.49e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—EGFR—bone cancer	3.9e-06	5.48e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KIT—bone cancer	3.88e-06	5.44e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—MDM2—bone cancer	3.88e-06	5.44e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MDM2—bone cancer	3.87e-06	5.43e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—JUN—bone cancer	3.86e-06	5.42e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—JUN—bone cancer	3.83e-06	5.37e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TGFBR2—bone cancer	3.82e-06	5.36e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—JUN—bone cancer	3.82e-06	5.36e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—DHFR—bone cancer	3.79e-06	5.32e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MMP9—bone cancer	3.76e-06	5.27e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—EGFR—bone cancer	3.73e-06	5.23e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—KIT—bone cancer	3.72e-06	5.23e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MDM2—bone cancer	3.69e-06	5.18e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MDM2—bone cancer	3.65e-06	5.13e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—BRAF—bone cancer	3.65e-06	5.12e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KIT—bone cancer	3.62e-06	5.07e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KIT—bone cancer	3.61e-06	5.06e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—EGFR—bone cancer	3.6e-06	5.06e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IGF1R—bone cancer	3.6e-06	5.05e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—BRAF—bone cancer	3.58e-06	5.03e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—EGFR—bone cancer	3.58e-06	5.02e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ENO2—bone cancer	3.56e-06	5e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GNA11—bone cancer	3.54e-06	4.97e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PTGS2—bone cancer	3.52e-06	4.94e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—BRAF—bone cancer	3.5e-06	4.91e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—TP53—bone cancer	3.48e-06	4.88e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—JUN—bone cancer	3.45e-06	4.84e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—JUN—bone cancer	3.44e-06	4.83e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—BRAF—bone cancer	3.4e-06	4.77e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—BRAF—bone cancer	3.39e-06	4.76e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—JUN—bone cancer	3.37e-06	4.73e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—JUN—bone cancer	3.36e-06	4.72e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MMP9—bone cancer	3.36e-06	4.71e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ENO2—bone cancer	3.36e-06	4.71e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—TP53—bone cancer	3.34e-06	4.68e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—DHFR—bone cancer	3.3e-06	4.64e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MMP9—bone cancer	3.27e-06	4.59e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KIT—bone cancer	3.25e-06	4.56e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—EGFR—bone cancer	3.23e-06	4.53e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CYP3A4—bone cancer	3.21e-06	4.51e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—JUN—bone cancer	3.21e-06	4.5e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.2e-06	4.49e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KIT—bone cancer	3.18e-06	4.46e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—MDM2—bone cancer	3.18e-06	4.46e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—EGFR—bone cancer	3.17e-06	4.45e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MMP9—bone cancer	3.12e-06	4.38e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—DHFR—bone cancer	3.11e-06	4.37e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GNA11—bone cancer	3.09e-06	4.33e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MDM2—bone cancer	3.06e-06	4.29e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—BRAF—bone cancer	3.05e-06	4.29e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—EGFR—bone cancer	3.04e-06	4.26e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—EGFR—bone cancer	3.01e-06	4.22e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—EGFR—bone cancer	3e-06	4.21e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MDM2—bone cancer	3e-06	4.21e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—BRAF—bone cancer	2.99e-06	4.2e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—EGFR—bone cancer	2.98e-06	4.18e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MDM2—bone cancer	2.93e-06	4.12e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—EGFR—bone cancer	2.93e-06	4.11e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GNA11—bone cancer	2.91e-06	4.08e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MDM2—bone cancer	2.85e-06	4e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ENO2—bone cancer	2.84e-06	3.99e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MDM2—bone cancer	2.84e-06	3.99e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PTGS2—bone cancer	2.83e-06	3.97e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CYP3A4—bone cancer	2.8e-06	3.93e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—EGFR—bone cancer	2.78e-06	3.9e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—EGFR—bone cancer	2.77e-06	3.89e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—JUN—bone cancer	2.76e-06	3.87e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GSTP1—bone cancer	2.75e-06	3.86e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—EGFR—bone cancer	2.71e-06	3.81e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—EGFR—bone cancer	2.71e-06	3.8e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTGS2—bone cancer	2.7e-06	3.79e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—JUN—bone cancer	2.66e-06	3.73e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—EGFR—bone cancer	2.65e-06	3.72e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—EGFR—bone cancer	2.65e-06	3.71e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CYP3A4—bone cancer	2.64e-06	3.7e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—DHFR—bone cancer	2.64e-06	3.7e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—JUN—bone cancer	2.61e-06	3.66e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KIT—bone cancer	2.61e-06	3.66e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MMP9—bone cancer	2.58e-06	3.63e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MDM2—bone cancer	2.56e-06	3.59e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—bone cancer	2.55e-06	3.58e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MMP9—bone cancer	2.54e-06	3.56e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—EGFR—bone cancer	2.52e-06	3.54e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MDM2—bone cancer	2.51e-06	3.52e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—EGFR—bone cancer	2.5e-06	3.5e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTGS2—bone cancer	2.48e-06	3.48e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—JUN—bone cancer	2.48e-06	3.47e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—JUN—bone cancer	2.47e-06	3.46e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GNA11—bone cancer	2.46e-06	3.46e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—BRAF—bone cancer	2.45e-06	3.44e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MMP9—bone cancer	2.41e-06	3.38e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MMP9—bone cancer	2.4e-06	3.37e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GSTP1—bone cancer	2.39e-06	3.36e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTGS2—bone cancer	2.29e-06	3.22e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—bone cancer	2.28e-06	3.2e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSTP1—bone cancer	2.26e-06	3.17e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP3A4—bone cancer	2.23e-06	3.14e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—JUN—bone cancer	2.22e-06	3.12e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.22e-06	3.12e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—bone cancer	2.22e-06	3.12e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ENO2—bone cancer	2.19e-06	3.08e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—JUN—bone cancer	2.18e-06	3.06e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—EGFR—bone cancer	2.17e-06	3.05e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MMP9—bone cancer	2.16e-06	3.04e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MMP9—bone cancer	2.12e-06	2.97e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—bone cancer	2.12e-06	2.97e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EGFR—bone cancer	2.09e-06	2.93e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MDM2—bone cancer	2.05e-06	2.88e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EGFR—bone cancer	2.05e-06	2.88e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—DHFR—bone cancer	2.04e-06	2.86e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—EGFR—bone cancer	2e-06	2.81e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EGFR—bone cancer	1.95e-06	2.73e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EGFR—bone cancer	1.94e-06	2.72e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTP1—bone cancer	1.91e-06	2.68e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GNA11—bone cancer	1.9e-06	2.67e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—JUN—bone cancer	1.79e-06	2.51e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—bone cancer	1.75e-06	2.46e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EGFR—bone cancer	1.75e-06	2.45e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MMP9—bone cancer	1.74e-06	2.44e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—bone cancer	1.72e-06	2.42e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EGFR—bone cancer	1.71e-06	2.4e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—bone cancer	1.63e-06	2.29e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—bone cancer	1.63e-06	2.29e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTP1—bone cancer	1.47e-06	2.07e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—bone cancer	1.47e-06	2.06e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—bone cancer	1.44e-06	2.02e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTGS2—bone cancer	1.42e-06	2e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EGFR—bone cancer	1.4e-06	1.97e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS2—bone cancer	1.24e-06	1.74e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—bone cancer	1.18e-06	1.65e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS2—bone cancer	1.17e-06	1.64e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS2—bone cancer	9.9e-07	1.39e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS2—bone cancer	7.64e-07	1.07e-05	CbGpPWpGaD
